FM
fazen.markets
healthcare·esfritzh

Inhibrx Ozekibart Hits 62.7% ORR in Ewing Sarcoma Trial

0h ago|5 min readStandard
FM

Fazen Markets

Source: SEC EDGAR

Written by AI from a primary source ·

inhibrx-biosciencesozekibartinbrx-109ewing-sarcomaoncology-data
Sponsoredby Fazen Capital

AiX — Free Expert Advisor

Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.

Myfxbook verified No subscription XAUUSD M15
Get Free EA

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.

Key Takeaways

  • 1Ozekibart roughly doubled historical response rates in relapsed Ewing sarcoma, but single-arm data in a rare disease still needs a regulatory path.

Partner

Trade the Markets Discussed in This Article

Regulated Broker Competitive Spreads

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Inhibrx Biosciences (Nasdaq: INBX) announced on 17 November 2026 that its investigational DR5 agonist ozekibart, combined with irinotecan and temozolomide, produced a 62.7% overall response rate in 51 response-evaluable patients with relapsed or refractory Ewing sarcoma, with an 86.3% disease control rate, according to the company's release tied to the CTOS 2026 Annual Meeting. Median progression-free survival was 6.0 months. The company said it intends to advance the program rapidly.

Context — Why Does This Ewing Sarcoma Data Matter Now?

The company supplied its own historical benchmark. Irinotecan and temozolomide alone in relapsed or refractory Ewing sarcoma typically yield an overall response rate of roughly 15% to 30% and a median progression-free survival of about 3 to 4 months.

The ozekibart combination roughly doubles the low end of that response range and extends median progression-free survival by two to three months against the same comparator. That gap is the entire investment case: the trial is not measuring ozekibart against placebo, it is measuring it against the backbone chemotherapy that already defines standard care in this setting.

The population matters as much as the number. These are patients who have exhausted effective options, per the company's description, and 60 patients were enrolled and treated as of the 18 September 2026 data cutoff, including 9 adolescents. Twenty-two remained on active treatment at the cutoff.

What triggered disclosure now is the CTOS 2026 Annual Meeting, where the data will be presented as a poster on 19 November 2026 by Varun Monga, M.D. The company also disclosed that the FDA accepted for filing its biologics license application for ozekibart in conventional chondrosarcoma, a separate indication.

The company framed the results through its chief executive, Mark Lappe, who said the response rate and durability are "particularly compelling in a population that has exhausted effective options." That is the company's characterization, not an independent adjudication.

Data — What the Ozekibart Numbers Show

The headline figures come from 51 response-evaluable patients out of 60 treated. Two patients achieved complete responses and 30 achieved partial responses, summing to the 62.7% overall response rate. Twelve additional patients had stable disease, producing the 86.3% disease control rate.

Measurable tumor reduction from baseline occurred in 43 of 51 response-evaluable patients, or 84.3%. That is a broader measure than response rate and indicates the drug is shrinking tumors in most patients who reach evaluation, not only in the responders counted under RECIST-style criteria.

MetricOzekibart + IRI/TMZHistorical IRI/TMZ alone
Overall response rate62.7%~15% to 30%
Median PFS6.0 months~3 to 4 months
Disease control rate86.3%Not disclosed

The median progression-free survival carried a 95% confidence interval of 4.6 to 7.4 months. Durable clinical benefit beyond 6 months was observed in 18 patients: 1 complete response, 1 stable disease, and 16 partial responses.

One patient maintained an ongoing partial response for more than two years. At the cutoff, 14 response-evaluable patients remained progression-free, including 2 with a progression-free survival duration exceeding 12 months.

On safety, the company said the combination showed an acceptable and manageable profile consistent with the known cytotoxic toxicities of irinotecan and temozolomide and with DR5 agonism, with no evidence of unexpected cumulative hepatotoxicity. The company did not disclose the terms of any regulatory pathway for the Ewing sarcoma indication.

Analysis — Which Tickers and Sectors Are Exposed?

Inhibrx carries the direct exposure through INBX. The read-through is narrower than a broad oncology rally, because ozekibart targets a specific mechanism and a specific rare tumor type.

Ewing sarcoma is a small commercial pool. The company cited approximately 300 new U.S. diagnoses each year and an estimated 2,500 people in the U.S. currently living with the disease. That scale limits near-term revenue even under approval, which is why the conventional chondrosarcoma filing, already accepted by the FDA, carries separate weight in the equity story.

The second-order beneficiaries are the contract research and manufacturing organizations supporting the trial and the specialty sarcoma centers running the protocol. Those exposures are diffuse and the company gave no spend figures, so no magnitude can be attached.

The counter-argument is trial design. This is a Phase 1/2 expansion study, not a randomized controlled trial, and 51 response-evaluable patients is a small denominator. Single-arm response rates in heavily pretreated populations can be inflated by patient selection, and the confidence interval on median progression-free survival spans 4.6 to 7.4 months, wide enough to overlap the upper end of the historical range.

Positioning reflects that tension. Investors holding INBX are underwriting a regulatory path in a rare indication plus a broader DR5 platform, while skeptics point to the absence of a randomized comparator and the small addressable population.

Outlook — What to Watch Next

The immediate catalyst is the CTOS poster session on 19 November 2026, where the full dataset becomes available for independent scrutiny. Poster materials will be posted in the investor portal's Events & Presentations section.

The company said it looks forward to discussing the results with the FDA, which makes any regulatory meeting or guidance on the Ewing sarcoma program the next substantive milestone. No timeline for that interaction was disclosed.

The FDA has already accepted for filing the biologics license application for ozekibart in conventional chondrosarcoma, and the review clock on that filing runs on its own schedule. Any action date tied to that application would move the equity independently of the Ewing sarcoma data.

For INBX, the key watch items are whether the CTOS presentation adds mature durability data beyond the 6-month cutoff and whether the company discloses a registration strategy for Ewing sarcoma. Without a stated path, the 62.7% response rate remains a strong signal without a defined destination.

Frequently Asked Questions

What does a 62.7% overall response rate mean for patients?

It means 32 of the 51 evaluable patients saw their tumors shrink by a defined threshold, with 2 complete responses and 30 partial responses. The company also reported that 43 of 51 patients, or 84.3%, had measurable tumor reduction from baseline, a wider group than the formal responders. These are heavily pretreated patients with relapsed or refractory disease.

Why did Inhibrx announce this data now?

The timing is tied to the Connective Tissue Oncology Society 2026 Annual Meeting, where the results will be presented as a poster on 19 November 2026 by Dr. Varun Monga. The data cutoff for the analysis was 18 September 2026. The company paired the disclosure with news that the FDA accepted its filing for ozekibart in conventional chondrosarcoma.

What happens next for the ozekibart program?

The company said it intends to discuss the results with the FDA and to advance its plans, though it did not disclose a meeting date or a registration strategy for Ewing sarcoma. Separately, the accepted chondrosarcoma application proceeds through review. The CTOS poster materials will be published in the company's investor portal.

Bottom Line

Ozekibart roughly doubled historical response rates in relapsed Ewing sarcoma, but single-arm data in a rare disease still needs a regulatory path.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.

Sponsored — AiX

Trade XAUUSD on autopilot — free Expert Advisor

AiX is our free MetaTrader 5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.

Get Free EA

PartnerPosition yourself for the macro moves discussed above

Start Trading
Share

Stay informed

Get market analysis delivered to your inbox.

Join 18,500+ investors

Sponsored

Ready to trade the markets?

Open a demo account in 30 seconds. No deposit required.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Related